Cargando…

Neurosarcoidosis: a clinical approach to diagnosis and management

Sarcoidosis is a rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. Our understanding of neurosarcoidosis has evolved from early descriptions of a uveoparotid fever to include presentations involving every part of the neural axis. The diagnosis...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibitoye, Richard T., Wilkins, A., Scolding, N. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413520/
https://www.ncbi.nlm.nih.gov/pubmed/27878437
http://dx.doi.org/10.1007/s00415-016-8336-4
_version_ 1783233191272775680
author Ibitoye, Richard T.
Wilkins, A.
Scolding, N. J.
author_facet Ibitoye, Richard T.
Wilkins, A.
Scolding, N. J.
author_sort Ibitoye, Richard T.
collection PubMed
description Sarcoidosis is a rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. Our understanding of neurosarcoidosis has evolved from early descriptions of a uveoparotid fever to include presentations involving every part of the neural axis. The diagnosis should be suspected in patients with sarcoidosis who develop new neurological symptoms, those presenting with syndromes highly suggestive of neurosarcoidosis, or neuro-inflammatory disease where more common causes have been excluded. Investigation should look for evidence of neuro-inflammation, best achieved by contrast-enhanced brain magnetic resonance imaging and cerebrospinal fluid analysis. Evidence of sarcoidosis outside the nervous system should be sought in search of tissue for biopsy. Skin lesions should be identified and biopsies taken. Chest radiography including high-resolution computed tomography is often informative. In difficult cases, fluorodeoxyglucose positron emission tomography and gallium-67 imaging may identify subclinical disease and a target for biopsy. Symptomatic patients should be treated with corticosteroids, and if clinically indicated other immunosuppressants such as hydroxychloroquine, azathioprine, cyclophosphamide or methotrexate should be added. Anti-tumour necrosis factor alpha therapies may be considered in refractory disease but caution should be exercised as there is evidence to suggest they may unmask disease.
format Online
Article
Text
id pubmed-5413520
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-54135202017-05-19 Neurosarcoidosis: a clinical approach to diagnosis and management Ibitoye, Richard T. Wilkins, A. Scolding, N. J. J Neurol Neurological Update Sarcoidosis is a rare but important cause of neurological morbidity, and neurological symptoms often herald the diagnosis. Our understanding of neurosarcoidosis has evolved from early descriptions of a uveoparotid fever to include presentations involving every part of the neural axis. The diagnosis should be suspected in patients with sarcoidosis who develop new neurological symptoms, those presenting with syndromes highly suggestive of neurosarcoidosis, or neuro-inflammatory disease where more common causes have been excluded. Investigation should look for evidence of neuro-inflammation, best achieved by contrast-enhanced brain magnetic resonance imaging and cerebrospinal fluid analysis. Evidence of sarcoidosis outside the nervous system should be sought in search of tissue for biopsy. Skin lesions should be identified and biopsies taken. Chest radiography including high-resolution computed tomography is often informative. In difficult cases, fluorodeoxyglucose positron emission tomography and gallium-67 imaging may identify subclinical disease and a target for biopsy. Symptomatic patients should be treated with corticosteroids, and if clinically indicated other immunosuppressants such as hydroxychloroquine, azathioprine, cyclophosphamide or methotrexate should be added. Anti-tumour necrosis factor alpha therapies may be considered in refractory disease but caution should be exercised as there is evidence to suggest they may unmask disease. Springer Berlin Heidelberg 2016-11-22 2017 /pmc/articles/PMC5413520/ /pubmed/27878437 http://dx.doi.org/10.1007/s00415-016-8336-4 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Neurological Update
Ibitoye, Richard T.
Wilkins, A.
Scolding, N. J.
Neurosarcoidosis: a clinical approach to diagnosis and management
title Neurosarcoidosis: a clinical approach to diagnosis and management
title_full Neurosarcoidosis: a clinical approach to diagnosis and management
title_fullStr Neurosarcoidosis: a clinical approach to diagnosis and management
title_full_unstemmed Neurosarcoidosis: a clinical approach to diagnosis and management
title_short Neurosarcoidosis: a clinical approach to diagnosis and management
title_sort neurosarcoidosis: a clinical approach to diagnosis and management
topic Neurological Update
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413520/
https://www.ncbi.nlm.nih.gov/pubmed/27878437
http://dx.doi.org/10.1007/s00415-016-8336-4
work_keys_str_mv AT ibitoyerichardt neurosarcoidosisaclinicalapproachtodiagnosisandmanagement
AT wilkinsa neurosarcoidosisaclinicalapproachtodiagnosisandmanagement
AT scoldingnj neurosarcoidosisaclinicalapproachtodiagnosisandmanagement